2seventy bio, Inc. (TSVT) and its partner Bristol Myers Squibb (BMY) announced the discontinuation of enrollment in the KarMMa-9 Phase 3 study for Abecma in newly diagnosed multiple myeloma. This decision is driven by a focus on capital allocation and accelerating the path to profitability. Despite the discontinuation, Abecma continues to see positive momentum in earlier lines of treatment, with expected U.S. revenue growth of 30% in the third quarter.